Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5739463

NC1CCc2ccc3c(ccn3S(=O)(=O)c3ccccc3)c2C1.O=C(O)C(F)(F)F

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 19/20 0.61
DRD2 P14416 4/20 0.45
DRD3 P35462 4/20 0.45
HTR1A P08908 2/20 0.41
HTR2A P28223 1/20 0.41
BCHE P06276 3/20 0.41
TPSAB1 Q15661 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR1F P30939 1/20 0.39
HTR7 P34969 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3205539 0.92 HTR6 (0.71) HTR6DRD2DRD3HTR1AHTR2A
Trifluoroacetic Acid SCHEMBL5737813 0.91 HTR6 (0.53) HTR6DRD2DRD3HTR1AHTR2A
SCHEMBL5738248 0.81 HTR6 (0.59) HTR6DRD2DRD3HTR1AHTR2A
SCHEMBL5739465 0.78 HTR6 (0.44) HTR6DRD2TPSAB1
SCHEMBL14216253 0.78 HTR6 (0.72) HTR6DRD2DRD3HTR1AHTR2A
SCHEMBL3205572 0.76 HTR6 (1.00) HTR6DRD2DRD3HTR1AHTR2A
SCHEMBL3209365 0.76 HTR6 (0.70) HTR6DRD2DRD3HTR1AHTR2A
Trifluoroacetic Acid SCHEMBL3621796 0.71 HTR6 (0.57) HTR6DRD2DRD3HTR1ATPSAB1
Trifluoroacetic Acid SCHEMBL4020079 0.70 HTR6 (0.55) HTR6DRD2DRD3HTR1AHTR2A
Trifluoroacetic Acid SCHEMBL1999860 0.69 HTR6 (0.40) HTR6DRD2DRD3HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148818-A1 Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders BIOVITRUM AB (SE) 2006-07-06 US claimed
EP-1675856-A1 NOVEL TETRAYDROSPIRO{PIPERIDINE-2,7'-PYRROLO [3,2]PYRIDINE} DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS BIOVITRUM AB (SE) 2006-07-05 EP claimed
WO-2005037834-A1 NOVEL TETRAYDROSPIRO{PIPERIDINE-2,7’ -PYRROLO[3,2-b]PYRIDINE DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS BIOVITRUM AB (SE) 2005-04-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148818-A1 Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders PTGDR, HTR6, HTR1B HTR6 2/4885DRD2 13/4885DRD3 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.